Tandem Diabetes Care
TNDM · NYSE · Healthcare · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$1.0B
Net margin
-20.2%
ROE
-131.9%
Revenue CAGR (2y)
+16.5%
EPS (FY2025)
-3.04
Net profit (FY2025)
$-204.7M
Ask MarketChacha about TNDM
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Aug 25, 2026
TNDM fell 3.02% with no company-specific news or filings on August 25; recent coverage focused on a consensus Hold rating and earlier Q2 results/guidance reaffirmation.
· confidence: low
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $1.0B | $-204.7M | -3.04 | -20.2% | -131.9% |
| FY2024 | $940.2M | $-96.0M | -1.47 | -10.2% | -36.5% |
| FY2023 | $747.7M | $-222.6M | -3.43 | -29.8% | -71.0% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $254.6M | $-21.2M | -0.31 | -8.3% |
| 2026Q1 | $247.2M | $-20.4M | -0.30 | -8.2% |
| 2025Q4 | $290.4M | $-589,000 | -0.01 | -0.2% |
| 2025Q3 | $249.3M | $-21.2M | -0.31 | -8.5% |
| 2025Q2 | $240.7M | $-52.4M | -0.78 | -21.8% |
| 2025Q1 | $234.4M | $-130.6M | -1.97 | -55.7% |
| 2024Q4 | $282.6M | $755,000 | 0.01 | 0.3% |
| 2024Q3 | $244.0M | $-23.3M | -0.35 | -9.5% |
| 2024Q2 | $221.9M | $-30.8M | -0.47 | -13.9% |
| 2024Q1 | $191.7M | $-42.7M | -0.65 | -22.3% |
| 2023Q4 | $196.8M | $-30.0M | -0.46 | -15.2% |
| 2023Q3 | $185.6M | $-33.0M | -0.51 | -17.8% |
| 2023Q2 | $195.9M | $-35.8M | -0.55 | -18.3% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/6/2026material
- SEC8/6/2026
- SEC5/15/2026material
- SEC5/7/2026material
- SEC5/7/2026
- SEC2/19/2026material
- SEC2/19/2026
2025
- SEC12/30/2025material
- SEC11/12/2025material
- SEC11/6/2025material
- SEC11/6/2025
- SEC8/7/2025material
- SEC8/6/2025material
- SEC8/6/2025
In the news
- Tandem Diabetes Care stock gains after recent rally in diabetes techAD HOC NEWS · 9/1/2026
- Tandem Diabetes Care (TNDM) Edges Higher to $21.49, Holding Above Key Support - Growth ETFvinanet.vn · 8/28/2026
- Innovative Insulin Pumps Drive Optimism for Tandem, Beta BionicsBenzinga · 8/21/2026
- Tandem (TNDM) Earnings Brief: Profit Per Share Clears Its Benchmark in the Current Update; Price Action: Shares Finish 6.63% Up at the Close - Earnings Season Previewvinanet.vn · 8/19/2026
- Tandem Diabetes (TNDM) CFO vests RSUs as shares withheld for taxStock Titan · 8/18/2026
- Tandem Diabetes (NASDAQ: TNDM) exec nets 475 shares after RSU vestingStock Titan · 8/18/2026
- Tandem Diabetes (NASDAQ: TNDM) EVP issued 2,827 shares, 809 withheldStock Titan · 8/18/2026
- Tandem Diabetes (NASDAQ: TNDM) CEO vests 15,916 RSUs as shares withheld for taxStock Titan · 8/18/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.